Search for a trial

Clinical Performance Study Plan (CPSP) for the use of GenDx CDx Tedopi for subject enrollment on to the OSE Immunotherapeutics Phase 3 trial (OSE2101C302) of OSE2101 versus docetaxel in HLA-A*02 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to immune checkpoint inhibitor (ARTEMIA)

This clinical performance study/clinical investigation will evaluate the safety and effectiveness of GenDx CDx Tedopi in identifying HLA-A*02 status in metastatic NSCLC subjects who may be eligible for treatment with OSE2101.

An exploratory, non-interventional, single-center study to characterize a set of immune cells in a range of dermatologic diseases

Primary To evaluate the prevalence of specific immune cell subsets in a range of IMID dermatologic disease patients, both between diseases and compared to healthy volunteers  Secondary To evaluate the variability in specific immune cell…